APA (7th ed.) Citation

Chari, A., van de Donk, N. W. C. J., Dholaria, B., Weisel, K., Mateos, M., Goldschmidt, H., . . . Wäsch, R. (2025). Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood, 146(24), . https://doi.org/10.1182/blood.2025029360

Chicago Style (17th ed.) Citation

Chari, Ajai, et al. "Talquetamab Plus Daratumumab for the Treatment of Relapsed or Refractory Multiple Myeloma in the TRIMM-2 Study." Blood 146, no. 24 (2025). https://doi.org/10.1182/blood.2025029360.

MLA (9th ed.) Citation

Chari, Ajai, et al. "Talquetamab Plus Daratumumab for the Treatment of Relapsed or Refractory Multiple Myeloma in the TRIMM-2 Study." Blood, vol. 146, no. 24, 2025, https://doi.org/10.1182/blood.2025029360.